Knight Therapeutics Inc.GUD.TOReports Thu, Nov 5 · Third Quarter 2026
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX · Canada · knighttx.com
Knight Therapeutics Inc. is a pan-American specialty pharmaceutical company focused on acquiring, in-licensing, and commercializing innovative prescription pharmaceuticals in Canada and Latin America. The company operates in Canada and 10 Latin American countries with over 700 employees globally, generating the majority of its revenue from Brazil. Knight is headquartered in Montreal, Quebec.
Key ratios
Operating cash flow growth
1068.6%TTM
2025
90.1%2024
1.0%2023
-20.1%
EPS growth
-43.4%TTM
FCF / Sales
19.8%TTM
2025
14.9%2024
9.1%2023
10.7%
Net margin
1.1%TTM
2025
-1.2%2024
1.2%2023
-5.1%
ROA
0.8%TTM
2025
-0.2%2024
0.5%2023
0.4%
ROE
0.7%TTM
2025
-0.7%2024
0.6%2023
-2.1%
Revenue growth
36.9%TTM
2025
21.2%2024
13.1%2023
11.8%
Recent news
Notice of Knight Therapeutics' Third Quarter 2026 Results Conference Call
Knight Therapeutics Announces Regulatory Approval of NIKTIMVO® in Brazil
Knight Therapeutics Announces Launch of TAVALISSE® in Brazil
Knight Therapeutics Enters into Exclusive Distribution Agreement with Kyowa Kirin International for Poteligeo® (Mogamulizumab)
Knight Therapeutics Announces Regulatory Submission of GEMTESA in Canada
Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Colombia
Knight Therapeutics Announces Supplemental Regulatory Submission for MINJUVI (tafasitamab) in Brazil
Knight Therapeutics Announces Launch of WYNZORA® in Canada
Knight Therapeutics Reports Second Quarter 2026 Results
Notice of Knight Therapeutics' Second Quarter 2026 Results Conference Call
Track GUD.TO in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer